In the iToBoS project we will follow two slightly different data flows depending on the point of origin of the patient’s data, due to differences between data protection regulation in Europe vs. Australia.
Soon it will be autumn, the season of changing leaves- and of grant reviews! And with more and more research funders demanding patient involvement, it's also the time for many of us patient advocates to review grants.
Artificial Intelligence (AI) has become an important tool in healthcare in recent years. AI has the ability to analyze large amounts of data and make predictions that can aid doctors in their diagnoses and treatments. This technology has the potential to revolutionize the healthcare industry and improve patient outcomes.
From December 1st, 2022 a new partner officially joined to the iToBoS consortium: Canfield Scientific GMBH. Due the termination of Barco NV’s activities in the project on M18 (September 2022), it was necessary to include a new partner to replace it.
The EU General Data Protection Regulation (GDPR) and other similar regulations set out many restrictions on the processing of per- sonal data. Similar laws and regulations are being enacted in additional states and countries around the world. Adhering to these regulations can be a complex and costly task.
In today's digital age, the confluence of art, science, and technology is opening doors to innovative approaches to familiar challenges.
Skin cancer, especially melanoma, has been on the rise in recent years, and it is the leading cause of fatality among all types of skin cancers. Early detection and treatment of melanoma can be effective in remedying the disease.
Interview with Violeta Astratinei, Core member of Melanoma Patient Network Europe and Founder of Melanom Romania.
This videoblog presents the webinar "How liquid lenses solve optical challenges in iToBoS" in full version of about 45 minutes of duration that includes the most technical sections about optical design..
This videoblog presents How liquid lenses solve optical challenges, in an executive version aimed at a broader audience.